THR-βAgonist for Nonalcoholic Steatohepatitis Treatment:Challenges of a Promising Drug  

作　　者：Feng Xue Lai Wei 

机构地区：[1]School of Clinical Medicine,Tsinghua University,Beijing,China [2]Hepatopancreatobiliary Center,Beijing Tsinghua Changgung Hospital,Tsinghua University,Beijing,China

出　　处：《Journal of Clinical and Translational Hepatology》2024年第8期755-757,共3页临床与转化肝病杂志（英文版）

摘　　要：Introduction.The incidence of nonalcoholic steatohepatitis(NASH)is in-creasing.Reesmetirom,a thyroid hormone receptorβTHR-βagonist,has demonstrated a good safety profile in published phase 2 and phase 3 studies,meeting the U.S.Food and Drug Administration(FDA)-required histological endpoint for efficacy.Consequently,on March 14,2024,resmetirom became the first drug to receive FDA approval for the treatment of NASH patients with fibrosis,marking a significant milestone in the field of hepatology.However,there are still some challenges in the clinical application of resmetirom.

关 键 词：THR HEPATITIS HISTOLOGICAL 

分 类 号：R575.5[医药卫生—消化系统]